Introduction
============

Nasopharyngeal cancer (NPC) is a fast-growing tumor which features distant metastasis and frequent nodal at diagnosis time.[@b1-ott-10-1433] Epstein-Barr virus (EBV) infection has been demonstrated as a major risk factor for NPC.[@b2-ott-10-1433] Besides, alcohol consumption and cigarette smoking could also increase the risk of NPC.[@b3-ott-10-1433] Laryngeal cancer (LC) is a common malignancy in the head and neck region.[@b4-ott-10-1433] Evidences have indicated that cigarette smoking and alcohol consumption play important roles in the development of the cancer.[@b5-ott-10-1433] Recent studies indicate that carcinogen-metabolizing genes could modulate individual susceptibility to cancers. Polymorphisms of these genes may influence carcinogen activation/detoxification by altering the expression and function of the genes.

Xenobiotics could be detoxified by the GSTM1 and GSTT1 enzymes. These phase II enzymes are involved in the detoxification of benzopyrene and polycyclic aromatic hydrocarbons (PAHs).[@b6-ott-10-1433] In addition, GSTM1 and GSTT1 serve as important factors in metabolizing carcinogens derived from tobacco smoke.[@b7-ott-10-1433] It has been observed that homozygous deletions of *GSTM1* and *GSTT1* genes bring about phenotypic absence of glutathione S-transferases (GSTs) activity.[@b8-ott-10-1433],[@b9-ott-10-1433] *GSTM1* and *GSTT1* null genotypes show an association with susceptibility to lung cancer or bladder cancer, which are induced by environmental factors.[@b10-ott-10-1433],[@b11-ott-10-1433]

*GSTM1* products are responsible for catalyzing the conjugation of glutathione to epoxide derivatives of PAHs, which are the major carcinogens in tobacco smoke.[@b12-ott-10-1433] Three different polymorphisms are observed in *GSTM1* gene.[@b13-ott-10-1433] Among them, the most important polymorphism (*GSTM1* null genotype) causes the inactivation of GSTM1 enzyme. The frequency of the null genotype ranges from 23% to 62% among different populations.[@b14-ott-10-1433]

This present meta-analysis aimed to investigate the association of *GSTM1* polymorphism with NPC and LC. The obtained outcome contributes to uncovering the pathogenesis of the cancers. Meanwhile, it contributes to clinical diagnosis of high-risk individuals for NPC and LC.

Methods
=======

Article search
--------------

Pubmed, Embase, and China National Knowledge Infrastructure (CNKI) databases were searched for potential articles without language limitation. The search date was limited to May 2017. The keywords used in the search were: *GSTM1*, polymorphism or mutation or variant, nasopharyngeal carcinoma or nasopharynx cancer, LC or laryngocarcinoma. The references of obtained articles were also checked for additional articles.

Inclusion and exclusion criteria
--------------------------------

The eligible articles had to meet the following criteria: (1) case-control studies; (2) articles investigating the relationship of *GSTM1* polymorphism with NPC or LC; (3) articles providing the genotype data in case and control groups. The articles would be excluded if they were: (1) review articles; (2) animal or in vitro experiments; (3) *GSTM1* polymorphism and risk of other cancers rather than NPC or LC.

Data extraction
---------------

Two authors were responsible for data extraction. The work was performed independently and any disagreements were resolved by discussion with a third author. The extracted information included: name of first author, publication year, country, ethnicity, experimental method, sample size, and genotypes' distribution in case and control groups. Quality of each study was evaluated by the method of Newcastle-Ottawa Scale (NOS).

Statistical analysis
--------------------

All the analyses were performed with Stata 12.0 software. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the relationship of *GSTM1* polymorphism with NPC or LC. *I*^2^ and *P*-value were used to assess the inter-study heterogeneity. *I*^2^\>50% or *P*\<0.05 indicates the presence of heterogeneity. If heterogeneity existed, the random-effects model was performed to pool data, otherwise, the fixed-effects model was used. Subgroup analyses based on ethnicity and source of control were initiated as well. Sensitivity analysis was conducted to assess the robustness of pooled results. Begg's funnel plot and Egger's regression analysis were used to evaluate the potential publication bias.

Results
=======

Article selection
-----------------

During the search, a total of 346 relevant articles were obtained. After screening the titles and abstracts, 213 records were excluded for review articles (n=82), *GSTM1* polymorphism and other cancers (n=67), and other genes and NPC or LC (n=64). The remaining 133 articles were evaluated for eligibility. During the evaluation, 101 articles were excluded for unavailable data (n=35), case studies (n=37), GSTM1 polymorphism and pathological condition (n=29). Finally, 32 eligible articles were selected for the present meta-analysis.[@b15-ott-10-1433]--[@b46-ott-10-1433] The detailed selection process was shown in [Figure 1](#f1-ott-10-1433){ref-type="fig"}. The basic information of included articles was listed in [Table 1](#t1-ott-10-1433){ref-type="table"}. The results about the quality assessment was shown in [Table 1](#t1-ott-10-1433){ref-type="table"} as well.

Relationship of *GSTM1* polymorphism with LC
--------------------------------------------

Random-effects model was used to analyze the association between *GSTM1* polymorphism and risk of LC (*P*=0.000). The pooled results indicated that *GSTM1* null genotype was related to increased risk of LC (OR =1.28, 95% CI =1.05--1.54). Subgroup analyses by ethnicity and source of control were performed as well ([Table 2](#t2-ott-10-1433){ref-type="table"}). The outcome indicated that *GSTM1* null genotype was correlated with enhanced risk of LC, compared with hospital-based (HB) population (OR =1.38, 95% CI =1.06--1.80) ([Figure 2](#f2-ott-10-1433){ref-type="fig"}). No positive results were observed in the analysis of ethnicity.

Relationship of *GSTM1* polymorphism with NPC
---------------------------------------------

Fixed-effects model was adopted to analyze the relationship of *GSTM1* polymorphism with NPC (*P*=0.417). Overall results indicated that *GSTM1* null genotype could increase the risk of NPC (OR =1.43, 95% CI =1.26--1.63). In the subgroup analysis by source of control, we found that *GSTM1* null genotype was still related to increased risk of NPC (population-based: OR =1.39, 95% CI =1.18--1.63; HB: OR =1.52, 95% CI =1.22--1.89) ([Figure 3](#f3-ott-10-1433){ref-type="fig"}).

Sensitivity analysis
--------------------

Sensitivity analysis was performed by deleting one study at a time. The analysis indicated that the pooled results were robust.

Publication bias detection
--------------------------

Begg's funnel plot and Egger's regression analysis were performed to detect the potential publication bias. The funnel plot seemed to be symmetrical (*P*=0.436) ([Figure 4](#f4-ott-10-1433){ref-type="fig"}). Egger's analysis also suggested the absence of publication bias (*P*=0.097).

Discussion
==========

GSTs, member of a super-family of detoxification enzymes, show important effects in resisting various environmental toxicants and chemical carcinogens. For the phase II detoxification enzymes, more than five classes (mu, sigma, pi, alpha, theta) of GSTs have been confirmed. Among these enzymes, only enzymes of GST-M (mu), GST-T (theta) and GST-P (pi) play important roles in the detoxification of carcinogenic electrophiles. Null mutations of *GSTM1* are linked with complete loss of enzyme activities for binding with genotoxic substrates, such as epoxides.[@b47-ott-10-1433] Cumulative data have confirmed that individuals with null genotype of *GSTM1* are more likely to develop various cancers such as colorectal cancer, prostate cancer, gastric cancer, lung cancer, liver cancer, bladder cancer, breast cancer, ovarian cancer, skin cancer, oral cancer, NPC, and LC.[@b25-ott-10-1433],[@b27-ott-10-1433],[@b48-ott-10-1433]--[@b57-ott-10-1433]

Accumulating data suggest that EBV infection, carcinogen exposure, and genetic susceptibility play an important role in NPC tumorigenesis. EBV infection is confirmed as a causal factor.[@b58-ott-10-1433] However, not all EBV-infected individuals would develop NPC, which indicates that other factors may be involved in the pathogenesis of the cancer, such as tumor promotion, lifestyle, and exposure to carcinogens.[@b59-ott-10-1433]--[@b61-ott-10-1433] Besides, susceptibility genes such as interferon-alpha, HLA-regions and *p53* alleles, and certain polymorphic genes encoding enzymes involved in metabolic activation and detoxification of xenobiotics have been regarded as risk factors.[@b62-ott-10-1433],[@b63-ott-10-1433] The null genotype of *GSTM1* is linked with the loss of enzyme activity for binding with genotoxic substrates, therefore, the individuals with *GSTM1* null are believed to be more likely to suffer NPC than individuals with normal genotype of *GSTM1*. The fact is that frequency of *GSTM1* null genotype is different among different ethnic groups, such as 45%--56% in Asians, 40%--58% in Caucasians, and 29%--30% in African-Americans.[@b64-ott-10-1433]--[@b67-ott-10-1433] In addition, the opinions on the relationship of *GSTM1* null genotype with risk of NPC were inconsistent among the published studies. Therefore, this meta-analysis was initiated to obtain a more accurate outcome. The outcome indicated that *GSTM1* null genotype could increase the risk of NPC (OR =1.43, 95% CI =1.26--1.63). A similar outcome was also observed in the subgroup analysis by source of control.

As for LC, smoking tobacco has been regarded as its main risk factor and only 1% of LC occurs among nonsmokers. However, not all smokers would develop LC. The incidence of LC is different among different countries and ethnic groups. Besides, LC cases exhibit geographic variations in distribution. These evidences indicate the important role of genetic susceptibility in the pathogenesis of LC. Tobacco contains aldehydes, nitrosamines, aromatic amines, and PAHs. These components can cause genetic mutations. There are many protective enzymes functioning in the deactivation or degradation of carcinogenic compounds, such as phase I enzymes (cytochrome p450, alcohol dehydrogenase) and phase II enzymes (N-acetyl transferases, GSTs). These enzymes, known as xenobiotic-metabolizing enzymes, commonly exist in the liver and have been found in the mucosa of the upper aerodigestive tract.[@b68-ott-10-1433] Phase II enzymes are involved in most metabolic detoxification processes of chemical carcinogens. Products of *GSTM1* gene contribute to conjugating glutathione to epoxide derivatives of PAHs. The associations of *GSTM1* null genotypes with tobacco-related cancers have been extensively reported, however, the role of *GSTM1* polymorphism in LC is still controversial. Our results, based on a meta-analysis, suggested that *GSTM1* null genotype was related to increased risk of LC (OR =1.28, 95% CI =1.05--1.54). The subgroup analysis by source of control also indicated that *GSTM1* null genotype was correlated with enhanced risk of LC.

This meta-analysis was performed with 32 eligible articles. The sample size was 10,185. The outcome showed certain priority in accuracy compared with other studies. However, several limitations existed in the analysis. Only *GSTM1* genetic polymorphism was analyzed, phase I and other phase II enzymes were not considered. Future analysis should focus much more on genes encoding these enzymes, which will contribute to uncovering the pathogenesis of NPC and LC. In addition, the occurrences of NPC and LC involve many risk factors. The analysis only considered the genetic factor and other environmental factors and genes should be investigated to get a much more complete outcome. Besides, significant heterogeneity existed in the analysis of LC, which might affect the accuracy of pooled results.

Subgroup analyses based on ethnicity and source of control were performed to identify the source of heterogeneity.

Conclusion
==========

*GSTM1* null genotype was related to increased risk of NPC and LC. The outcome will contribute to screening high-risk populations for NPC and LC.

We are indebted to the authors of the primary studies.
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![Article selection process. 32 eligible articles were included into the present meta-analysis.\
**Abbreviation:** CNKI, China National Knowledge Infrastructure.](ott-10-1433Fig1){#f1-ott-10-1433}

![Subgroup analysis by source of control about the association between *GSTM1* null genotype and risk of LC.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** LC, laryngeal cancer; OR, odds ratio; CI, confidence interval; PB, population-based; HB, hospital-based.](ott-10-1433Fig2){#f2-ott-10-1433}

![Subgroup analysis by source of control about the association between *GSTM1* null genotype and risk of NPC.\
**Abbreviations:** NPC, nasopharyngeal cancer; OR, odds ratio; CI, confidence interval; PB, population-based; HB, hospital-based.](ott-10-1433Fig3){#f3-ott-10-1433}

![Begg's funnel plot (NPC). The funnel plot seemed to be symmetrical (*P*=0.436).\
**Abbreviations:** NPC, nasopharyngeal cancer; OR, odds ratio; CI, confidence interval; SE, standard error.](ott-10-1433Fig4){#f4-ott-10-1433}

###### 

Basic information of included articles

  Cancers   Author                                   Year   Country   Method          Score   Case   Control         
  --------- ---------------------------------------- ------ --------- --------------- ------- ------ --------- ----- -----
  LC        Unal et al[@b26-ott-10-1433]             2004   Turkey    Real-time PCR   5       23     19        57    32
            Gajecka et al[@b27-ott-10-1433]          2005   Poland    PCR-RFLP        7       152    140       157   164
            Acar et al[@b28-ott-10-1433]             2006   Turkey    PCR             8       53     57        123   74
            To-Figueras et al[@b29-ott-10-1433]      2002   Spain     PCR-RFLP        8       108    96        103   100
            Hong et al[@b30-ott-10-1433]             2000   Korean    PCR             8       26     56        30    33
            Charzimichalis et al[@b31-ott-10-1433]   2010   Greece    PCR             8       14     74        14    88
            Jourenkova et al[@b32-ott-10-1433]       1998   France    PCR             9       51     78        82    90
            Tian et al[@b33-ott-10-1433]             2011   China     PCR             8       117    116       80    22
            Lourenco et al[@b34-ott-10-1433]         2011   Brazil    PCR-RFLP        7       23     14        76    66
            Yan and Zhou[@b35-ott-10-1433]           2003   China     PCR             7       12     30        56    52
            Li et al[@b36-ott-10-1433]               2004   China     PCR             7       39     50        95    69
            Morita et al[@b37-ott-10-1433]           1999   Japan     PCR             7       39     81        30    83
            Kihara et al[@b38-ott-10-1433]           1997   Japan     PCR             8       70     86        242   230
            Bardakci et al[@b39-ott-10-1433]         2003   Turkey    PCR             8       11     25        19    16
            Gattas et al[@b40-ott-10-1433]           2006   Brazil    PCR-RFLP        8       12     10        63    39
            Lei et al[@b41-ott-10-1433]              2003   China     PCR             7       17     45        28    28
            Matthias et al[@b42-ott-10-1433]         2003   German    PCR             7       114    151       83    95
            Risch et al[@b43-ott-10-1433]            2003   German    PCR-RFLP        9       118    127       116   135
            Gronau et al[@b44-ott-10-1433]           2003   German    PCR             8       107    80        71    68
            Jahnke et al[@b45-ott-10-1433]           1997   German    PCR-RFLP        8       118    51        104   112
            Biselli et al[@b46-ott-10-1433]          2006   Brazil    PCR             8       15     7         31    29
  NPC       Deng et al[@b15-ott-10-1433]             2004   China     PCR             7       35     56        71    64
            Jiang et al[@b16-ott-10-1433]            2011   China     PCR             7       85     97        215   157
            Cheng et al[@b17-ott-10-1433]            2003   China     PCR             8       141    173       168   169
            Guo et al[@b18-ott-10-1433]              2008   China     PCR             8       137    204       262   328
            Zhang[@b19-ott-10-1433]                  2012   China     PCR-CTPP        7       18     27        19    11
            Da et al[@b20-ott-10-1433]               2002   China     PCR             8       32     48        44    36
            Wei et al[@b21-ott-10-1433]              2010   China     PCR             7       48     48        336   305
            Deng et al[@b22-ott-10-1433]             2005   China     PCR             7       49     78        112   95
            Tiwawech et al[@b23-ott-10-1433]         2005   Japan     PCR             7       28     50        71    74
            Liao et al[@b24-ott-10-1433]             2005   China     PCR             7       30     50        40    32
            Nazar-Stewart et al[@b25-ott-10-1433]    1999   America   PCR             8       38     45        79    63

**Note:** Quality assessment of each study was performed by the method of Newcastle-Ottawa Scale and the score was calculated.

**Abbreviations:** PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PCR-CTPP, polymerase chain-reaction with the confronting-two-pair primer; NPC, nasopharyngeal cancer; LC, laryngeal cancer.

###### 

Pooled results of the present meta-analysis

  Cancers   Subgroup    Types       OR     95% CI       *P*-value for heterogeneity
  --------- ----------- ----------- ------ ------------ -----------------------------
  LC        Ethnicity   Caucasian   1.27   0.99--1.56   0.000
                        Asian       1.36   0.96--1.93   0.053
            Source of   PB          1.13   0.86--1.48   0.022
            control     HB          1.38   1.06--1.80   0.000
            Total       --          1.28   1.05--1.54   0.000
  NPC       Source of   PB          1.39   1.18--1.63   0.309
            control     HB          1.52   1.22--1.89   0.423
            Total       --          1.43   1.26--1.63   0.417

**Abbreviations:** LC, laryngeal cancer; NPC, nasopharyngeal cancer; OR, odds ratio; CI, confidence interval; PB, population-based; HB, hospital-based.
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